Weight Loss Leader Novo Nordisk Hits Buy Trigger In Stock Market ReboundInvestors Business Daily • 04/24/24
Novo Nordisk (NVO) Boasts Earnings & Price Momentum: Should You Buy?Zacks Investment Research • 04/23/24
Eight stock picks in AI, obesity drugs, e-commerce and other growth areas beyond the S&P 500Market Watch • 04/18/24
Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.Market Watch • 04/16/24
Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to KnowZacks Investment Research • 04/16/24
Novo Nordisk and Ginkgo Bioworks Are Teaming Up. Here's Why That's Bullish for Both Stocks.The Motley Fool • 04/15/24
Novo Nordisk and Eli Lilly weight loss drugs may not be a silver bullet, but they have huge potential, says leading US bankProactive Investors • 04/15/24
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating - Novo Nordisk (NYSE:NVO)Benzinga • 04/12/24
EU probe of weight loss and diabetes drugs like Wegovy, Ozempic finds no link to suicidal thoughtsCNBC • 04/12/24
Obesity-drug power couple Novo Nordisk and Eli Lilly still have room to run, analysts sayMarket Watch • 04/12/24